| abstract |
The present disclosure provides for chimeric hybrid factor VIII (FVIII) comprising FVIII and Fc against subjects at risk of developing an inhibitory FVIII immune response (including anti-FVIII antibodies and / or cell-mediated immunity). ) A method of administering a polypeptide is provided. This administration is sufficient to promote clotting and induce immune tolerance to FVIII. The chimeric polypeptide may comprise full length FVIII, or FVIII polypeptide comprising a deletion (eg, complete or partial deletion of the B domain). [Selection] Figure 1 |